Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif

GETAID (Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif) is a prominent French academic research organization dedicated to improving the treatment of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. Founded in 1984, the group coordinates a vast network of gastroenterologists across France and Europe to conduct high-quality clinical trials and observational studies. Their work primarily focuses on optimizing therapeutic strategies, evaluating the long-term efficacy of biologics, and developing personalized medicine approaches for patients with chronic intestinal inflammation. GETAID is globally recognized for its investigator-initiated trials that have significantly influenced clinical practice guidelines and treatment algorithms. The organization collaborates extensively with both academic institutions and the pharmaceutical industry to advance the field of gastroenterology.